The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
Abdelnour, Carla (Universitat Autònoma de Barcelona. Departament de Medicina)
Ferreira, Daniel (Karolinska Institutet (Estocolm, Suècia). Department of Neurobiology, Care Sciences and Society)
Oppedal, Ketil (Department of Electrical Engineering and Computer Science, University of Stavanger, Stavanger, Norway)
Cavallin, Lena (Karolinska University Hospital and Karolinska Institutet (Suècia))
Bousiges, Olivier (Hôpitaux Universitaire de Strasbourg (Estrasburg, França))
Wahlund, Lars-Olof (Karolinska Institutet (Estocolm, Suècia). Department of Neurobiology, Care Sciences and Society)
Hort, Jakub (Charles University (Praga, República Txeca))
Nedelska, Zuzana (Charles University (Praga, República Txeca))
Padovani, Alessandro (University of Brescia (Itàlia))
Pilotto, Andrea (University of Brescia, Brescia (Itàlia))
Bonanni, Laura (University G d'Annunzio of Chieti-Pescara (Chieti, Itàlia))
Kramberger, Milica G. (University of Ljubljana (Eslovènia))
Boada, Mercè (Institut Català de Neurociènces Aplicades)
Westman, Eric (King's College London)
Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau)
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau)
Blanc, Frédéric (Hôpitaux Universitaire de Strasbourg)
Aarsland, Dag (King's College London. Institute of Psychiatry, Psychology & Neuroscience)

Fecha:	2020
Resumen:	Alzheimer's disease (AD)-related pathology is frequently found in patients with dementia with Lewy bodies (DLB). However, it is unknown how amyloid-β and tau-related pathologies influence neurodegeneration in DLB. Understanding the mechanisms underlying brain atrophy in DLB can improve our knowledge about disease progression, differential diagnosis, drug development and testing of anti-amyloid and anti-tau therapies in DLB. We aimed at investigating the combined effect of CSF amyloid-β42, phosphorylated tau and total tau on regional brain atrophy in DLB in the European DLB (E-DLB) cohort. 86 probable DLB patients from the E-DLB cohort with CSF and MRI data were included. Random forest was used to analyze the association of CSF biomarkers (predictors) with visual rating scales for medial temporal lobe atrophy (MTA), posterior atrophy (PA) and global cortical atrophy scale-frontal subscale (GCA-F) (outcomes), including age, sex, education and disease duration as extra predictors. DLB patients with abnormal MTA scores had abnormal CSF Aβ42, shorter disease duration and older age. DLB patients with abnormal PA scores had abnormal levels of CSF Aβ42 and p-tau, older age, lower education and shorter disease duration. Abnormal GCA-F scores were associated with lower education, male sex, and older age, but not with any AD-related CSF biomarker. This study shows preliminary data on the potential combined effect of amyloid-β and tau-related pathologies on the integrity of posterior brain cortices in DLB patients, whereas only amyloid-β seems to be related to MTA. Future availability of α-synuclein biomarkers will help us to understand the effect of α-synuclein and AD-related pathologies on brain integrity in DLB.
Nota:	Altres ajuts: Carla Abdelnour has received honoraria from Zambon and Schwabe. Dr. Nedelska has been supported by IBRO-ISN fellowship 2018. Dr Aarsland has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and served as paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura. Dag Aarsland is a Royal Society Wolfson Research Merit Award Holder and would like to thank the Wolfson Foundation and the Royal Society for their support.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Lewy body disease ; Biomarkers ; Atrophy ; Alzheimer disease ; Neuroimaging
Publicado en:	NeuroImage. Clinical, Vol. 27 (july 2020) , ISSN 2213-1582

DOI: 10.1016/j.nicl.2020.102333
PMID: 32674011

9 p, 763.7 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados